It is Not a Curse! It is Neurofibromatosis 1 (NF1): A Case Report from Rural Kenya

Authors

  • Vonwicks C. Onyango Department of Medicine, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya https://orcid.org/0009-0004-6791-8809
  • Nicholas M. Mutuma Department of Outpatient, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya
  • Samuel M. Gachie Department of Outpatient, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya
  • Boniface Mutiso Department of Outpatient, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya
  • Nicholas Auma Department of Endoscopy, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya
  • William C. Fryda MD Department of Medicine, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya

DOI:

https://doi.org/10.54536/ajmsi.v3i1.2709

Keywords:

Neurofibromatosis 1, NF1, Von Recklinghausen Disease, Café-Au-Lait Macules, Neurofibromas, Skin Freckles, Kenya

Abstract

Neurofibromatosis 1 (NF1) is an autosomal dominant genetic disorder caused by mutations in the NF1 gene, with near complete penetrance and variable clinical presentation. Patients classically have café-au-lait macules, neurofibromas, skin freckles, and Lisch nodules, among other multisystemic features. Long-term management in a multidisciplinary team focuses on surveillance and treating complications. NF1 is a rare disease in Kenya, often leading to myths and misconceptions about its nature, especially among rural communities. We present a classical case from rural Kenya whose diagnosis was delayed by a belief that it was the result of a curse. We aim to highlight the importance of making this diagnosis and its linkage to a long-term care plan within a primary health care setting.

Downloads

Download data is not yet available.

Author Biography

Vonwicks C. Onyango, Department of Medicine, St. Joseph Rift Valley Hospital, Gilgil, Nakuru County, Kenya

 

 

References

DiMario, F. J., Jr., & Ramsby, G. (1998). Magnetic Resonance Imaging Lesion Analysis in Neurofibromatosis Type 1. Archives of Neurology, 55(4), 500-505. https://doi.org/10.1001/archneur.55.4.500

Ferner, R. E., Huson, S. M., Thomas, N., Moss, C., Willshaw, H., Evans, D. G., Upadhyaya, M., Towers, R., Gleeson, M., Steiger, C., & Kirby, A. (2007). Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2), 81-88. https://doi.org/10.1136/jmg.2006.045906

Gutmann, D. H., Ferner, R. E., Listernick, R. H., Korf, B. R., Wolters, P. L., & Johnson, K. J. (2017). Neurofibromatosis type 1. Nat Rev Dis Primers, 3, 17004. https://doi.org/10.1038/nrdp.2017.4

Lee, T. J., Chopra, M., Kim, R. H., Parkin, P. C., & Barnett-Tapia, C. (2023). Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis. Orphanet J Rare Dis, 18(1), 292. https://doi.org/10.1186/s13023-023-02911-2

Legius, E., Messiaen, L., Wolkenstein, P., Pancza, P., Avery, R. A., Berman, Y., Blakeley, J., Babovic-Vuksanovic, D., Cunha, K. S., Ferner, R., Fisher, M. J., Friedman, J. M., Gutmann, D. H., Kehrer-Sawatzki, H., Korf, B. R., Mautner, V. F., Peltonen, S., Rauen, K. A., Riccardi, V., . . . Plotkin, S. R. (2021). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med, 23(8), 1506-1513. https://doi.org/10.1038/s41436-021-01170-5

Masocco, M., Kodra, Y., Vichi, M., Conti, S., Kanieff, M., Pace, M., Frova, L., & Taruscio, D. (2011). Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis, 6, 11. https://doi.org/10.1186/1750-1172-6-11

Moutal, A., Yang, X., Li, W., Gilbraith, K. B., Luo, S., Cai, S., François-Moutal, L., Chew, L. A., Yeon, S. K., Bellampalli, S. S., Qu, C., Xie, J. Y., Ibrahim, M. M., Khanna, M., Park, K. D., Porreca, F., & Khanna, R. (2017). CRISPR/Cas9 editing of Nf1 gene identifies CRMP2 as a therapeutic target in neurofibromatosis type 1-related pain that is reversed by (S)-Lacosamide. Pain, 158(12), 2301-2319. https://doi.org/10.1097/j.pain.0000000000001002

Ochola, E. A., Karanja, D. M. S., & Elliott, S. J. (2021). The impact of Neglected Tropical Diseases (NTDs) on health and wellbeing in sub-Saharan Africa (SSA): A case study of Kenya. PLoS Negl Trop Dis, 15(2), e0009131. https://doi.org/10.1371/journal.pntd.0009131

Ortonne, N., Wolkenstein, P., Blakeley, J. O., Korf, B., Plotkin, S. R., Riccardi, V. M., Miller, D. C., Huson, S., Peltonen, J., Rosenberg, A., Carroll, S. L., Verma, S. K., Mautner, V., Upadhyaya, M., & Stemmer-Rachamimov, A. (2018). Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology, 91(2 Suppl 1), S5-s13. https://doi.org/10.1212/wnl.0000000000005792

Plotkin, S. R., Bredella, M. A., Cai, W., Kassarjian, A., Harris, G. J., Esparza, S., Merker, V. L., Munn, L. L., Muzikansky, A., Askenazi, M., Nguyen, R., Wenzel, R., & Mautner, V. F. (2012). Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One, 7(4), e35711. https://doi.org/10.1371/journal.pone.0035711

Plotkin, S. R., Messiaen, L., Legius, E., Pancza, P., Avery, R. A., Blakeley, J. O., Babovic-Vuksanovic, D., Ferner, R., Fisher, M. J., Friedman, J. M., Giovannini, M., Gutmann, D. H., Hanemann, C. O., Kalamarides, M., Kehrer-Sawatzki, H., Korf, B. R., Mautner, V. F., MacCollin, M., Papi, L., . . . Evans, D. G. (2022). Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med, 24(9), 1967-1977. https://doi.org/10.1016/j.gim.2022.05.007

Prada, C. E., Rangwala, F. A., Martin, L. J., Lovell, A. M., Saal, H. M., Schorry, E. K., & Hopkin, R. J. (2012). Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1. J Pediatr, 160(3), 461-467. https://doi.org/10.1016/j.jpeds.2011.08.051

Sanagoo, A., Jouybari, L., Koohi, F., & Sayehmiri, F. (2019). Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study. BMC Neurol, 19(1), 123. https://doi.org/10.1186/s12883-019-1338-y

Stewart, D. R., Korf, B. R., Nathanson, K. L., Stevenson, D. A., & Yohay, K. (2018). Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med, 20(7), 671-682. https://doi.org/10.1038/gim.2018.28

Tamura, R. (2021). Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis. Int J Mol Sci, 22(11). https://doi.org/10.3390/ijms22115850

Van Es, S., North, K. N., McHugh, K., & De Silva, M. (1996). MRI findings in children with neurofibromatosis type 1: a prospective study. Pediatr Radiol, 26(7), 478-487. https://doi.org/10.1007/bf01377205

Vernimmen, V., Paulussen, A. D. C., Dreesen, J., van Golde, R. J., Zamani Esteki, M., Coonen, E., van Buul-van Zwet, M. L., Homminga, I., Derijck, A., Brandts, L., Stumpel, C., & de Die-Smulders, C. E. M. (2023). Preimplantation genetic testing for Neurofibromatosis type 1: more than 20 years of clinical experience. Eur J Hum Genet, 31(8), 918-924. https://doi.org/10.1038/s41431-023-01404-x

Wilding, A., Ingham, S. L., Lalloo, F., Clancy, T., Huson, S. M., Moran, A., & Evans, D. G. (2012). Life expectancy in hereditary cancer predisposing diseases: an observational study. J Med Genet, 49(4), 264-269. https://doi.org/10.1136/jmedgenet-2011-100562

Downloads

Published

2024-05-15

How to Cite

Onyango, V. C., Mutuma, N. M., Gachie, S. M., Mutiso, B., Auma, N., & Fryda MD, W. C. (2024). It is Not a Curse! It is Neurofibromatosis 1 (NF1): A Case Report from Rural Kenya. American Journal of Medical Science and Innovation, 3(1), 107–111. https://doi.org/10.54536/ajmsi.v3i1.2709